Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859 | 0.90 | POLB (0.50) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL8055438 | 0.82 | POLB (0.42) | POLBLMNAKDM4EKMT2AHSD17B10 | |
| SCHEMBL1299 | 0.81 | SMN1; SMN2 (0.45) | POLBSMN1; SMN2RAB9AMAPTTSHR | |
| SCHEMBL20503314 | 0.79 | LMNA (0.44) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL6630242 | 0.78 | POLB (0.36) | POLBLMNASMN1; SMN2MAPTTSHR | |
| SCHEMBL973113 | 0.77 | LMNA (0.50) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL8043219 | 0.77 | TSHR (0.41) | POLBLMNASMN1; SMN2MAPTKDM4E | |
| SCHEMBL6713457 | 0.76 | LMNA (0.44) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4787730 | 0.76 | POLB (0.51) | POLBLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7699075 | 0.76 | LMNA (0.49) | POLBLMNASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270425-A1 | 3-(DIHYDRO-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-PROPOXYBENZENESULFONAMIDE DERIVATIVES AND METHODS OF USE | CONCERT PHARMACEUTICALS INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090197899-A1 | 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use | CONCERT PHARMACEUTICALS INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-20080194529-A1 | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20050069276-A1 | Deuterated pyrazolopyrimidinones and drugs containing said compounds | BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270425-A1 | 3-(DIHYDRO-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-PROPOXYBENZENESULFONAMIDE DERIVATIVES AND METHODS OF USE | PDE5A, PDE3A, PDE3B | POLB 700/4885LMNA 3008/4885SMN1; SMN2 2426/4885 |
| US-20090197899-A1 | 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use | PDE5A, PDE3A, PDE3B | POLB 700/4885LMNA 3008/4885SMN1; SMN2 2426/4885 |
| US-20050069276-A1 | Deuterated pyrazolopyrimidinones and drugs containing said compounds | CHRM3, MPL, PFKP | POLB 3458/4885LMNA 3278/4885SMN1; SMN2 894/4885 |
| US-20080194529-A1 | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS | PDE5A, PDE7A, PDE3A | POLB 1336/4885LMNA 2826/4885SMN1; SMN2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.